<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03838978</url>
  </required_header>
  <id_info>
    <org_study_id>CP0002 (formerly CLIN102918)</org_study_id>
    <nct_id>NCT03838978</nct_id>
  </id_info>
  <brief_title>Calypso Knee System Clinical Study, OUS</brief_title>
  <official_title>Evaluation of the Calypso Knee System for Symptom Relief in Subjects With Medial Knee Osteoarthritis, OUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moximed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moximed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and effectiveness of the Calypso Knee System when used in&#xD;
      subjects with symptomatic osteoarthritis of the medial compartment of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicenter clinical study of the Calypso Knee System. A total of 80 subjects&#xD;
      will be enrolled in this study at up to 14 investigational sites located in Europe and in the&#xD;
      United States (U.S.). A minimum of 35 subjects will be enrolled at up to 7 investigational&#xD;
      sites in Europe. Male or female subjects age 25 to 65 years, with a diagnosis of medial knee&#xD;
      osteoarthritis and study knee pain with an overall WOMAC pain score ≥ 40 (scale 0-100).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 8, 2019</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Arm Study Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Western Ontario and McMasters University Osteoarthritis Index (WOMAC) Pain</measure>
    <time_frame>Change at 24 months relative to baseline</time_frame>
    <description>The WOMAC Pain score is derived from a sub-section of the Knee injury and Osteoarthritis Outcome Score (KOOS) Knee Survey. The WOMAC Pain scores range from 0-100 with lower scores considered lower pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Western Ontario and McMasters University Osteoarthritis Index (WOMAC) Function</measure>
    <time_frame>Change at 24 months relative to baseline</time_frame>
    <description>The WOMAC Function score is derived from a sub-section of the Knee injury and Osteoarthritis Outcome Score (KOOS) Knee Survey. The WOMAC Function scores range from 0-100 with lower scores considered to have better function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events resulting in Secondary Surgical Interventions</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Incidence of Secondary Surgical Intervention due to implant related Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance of Implant Integrity by Radiographic Review</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Implant integrity will be assessed by radiographic review to verify that the implant is not disassembled</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Calypso Knee System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calypso Knee System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Calypso Knee System</intervention_name>
    <description>The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.</description>
    <arm_group_label>Calypso Knee System</arm_group_label>
    <other_name>Calypso System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants age - 25 to 65 years&#xD;
&#xD;
          2. Body Mass Index (BMI) of &lt; 35, Weight &lt; 300 lbs (136 kg)&#xD;
&#xD;
          3. Knee osteoarthritis pain on the inner side of knee that has continued after at least 6&#xD;
             months of non-operative treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptoms of osteoarthritis in the other knee or in lateral (outer) or patellofemoral&#xD;
             compartments of the target knee&#xD;
&#xD;
          2. Knee ligament or meniscal instability&#xD;
&#xD;
          3. Other bone or joint conditions such as Rheumatoid arthritis, Paget's disease,&#xD;
             Charcot's disease or general conditions such as allergy or hypersensitivity to certain&#xD;
             metals, active infection, certain neurological conditions, use of medication such as&#xD;
             steroids or chemotherapy that could impact study participation or results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Kraenzlin</last_name>
    <role>Study Director</role>
    <affiliation>Moximed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zagiel Med Hospital</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Medical Center</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chirurgii Kolana Dr Słynarskiego</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPORTO</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

